Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 20;13(1):1173.
doi: 10.1038/s41598-022-26832-5.

A comparison of pediatric inflammatory multisystem syndrome temporarily-associated with SARS-CoV-2 and Kawasaki disease

Collaborators, Affiliations

A comparison of pediatric inflammatory multisystem syndrome temporarily-associated with SARS-CoV-2 and Kawasaki disease

Markus Hufnagel et al. Sci Rep. .

Abstract

The connection between Pediatric Inflammatory Multisystem Syndrome (PIMS) and Kawasaki Disease (KD) is not yet fully understood. Using the same national registry, clinical features and outcome of children hospitalized in Germany, and Innsbruck (Austria) were compared. Reported to the registry were 395 PIMS and 69 KD hospitalized patients. Patient age in PIMS cases was higher than in KD cases (median 7 [IQR 4-11] vs. 3 [IQR 1-4] years). A majority of both PIMS and KD patients were male and without comorbidities. PIMS patients more frequently presented with organ dysfunction, with the gastrointestinal (80%), cardiovascular (74%), and respiratory (52%) systems being most commonly affected. By contrast, KD patients more often displayed dermatological (99% vs. 68%) and mucosal changes (94% vs. 64%), plus cervical lymph node swelling (51% vs. 34%). Intensive care admission (48% vs. 19%), pulmonary support (32% vs. 10%), and use of inotropes/vasodilators (28% vs. 3%) were higher among PIMS cases. No patients died. Upon patient discharge, potentially irreversible sequelae-mainly cardiovascular-were reported (7% PIMS vs. 12% KD). Despite differences in age distribution and disease severity, PIMS and KD cases shared many common clinical and prognostic characteristics. This supports the hypothesis that the two entities represent a syndrome continuum.

PubMed Disclaimer

Conflict of interest statement

Reinhard Berner received grants from the Federal State of Saxony, Germany. The study was partially supported by funding from the Federal State of Saxony, Germany. The Federal State of Saxony had no role in the design and conduct of the study. Jakob Armann received grants from the Federal State of Saxony, Germany. The study was partially supported by funding from the Federal State of Saxony, Germany. The Federal State of Saxony had no role in the design and conduct of the study. Jochen Schmitt received institutional funding for investigator-initiated research from Novartis, Sanofi, Pfizer, ALK, and acted as a consultant for Novartis, Sanofi, and Lilly in a function unrelated to this study. The other authors have no competing interests to disclose.

Figures

Figure 1
Figure 1
Weekly numbers of hospital-admitted cases of (A) pediatric COVID-19 and PIMS-all, as well as of cases with (B) PIMS-all and KD. Graphics created by using the software from www.datawrapper.de.
Figure 2
Figure 2
Age distribution of patients with (A) PIMS-all and KD, as well as of patients with (B) PIMS-non-KD and PIMS-KD.

References

    1. Zhu N, et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 2020;382:727–733. doi: 10.1056/NEJMoa2001017. - DOI - PMC - PubMed
    1. Mehta NS, et al. SARS-CoV-2 (COVID-19): what do we know about children? A systematic review. Clin. Infect. Dis. 2020;71:2469–2479. doi: 10.1093/cid/ciaa556. - DOI - PMC - PubMed
    1. Viner RM, et al. Systematic review of reviews of symptoms and signs of COVID-19 in children and adolescents. Arch. Dis. Child. 2021;106:802–807. doi: 10.1136/archdischild-2020-320972. - DOI - PubMed
    1. Nikolopoulou GB, Maltezou HC. COVID-19 in children: where do we stand? Arch. Med. Res. 2021;53:1–8. doi: 10.1016/j.arcmed.2021.07.002. - DOI - PMC - PubMed
    1. World Health Organization (WHO). Multisystem inflammatory syndrome in children and adolescents with COVID-19. https://www.who.int/news-room/commentaries/detail/multisystem-inflammato... (2020). Accessed 10 July 2022.

Publication types

Supplementary concepts

Associated data